Rifampicinによる肺結核治療の臨床的研究 : 第2報未治療肺結核に対するRFP・INH・PAS併用とSM・INH・PAS併用の治療効果比較

スポンサーリンク

概要

• 論文の詳細を見る

• This study deals with the clinical effects of Rifampicin (RFP) -isoniazid (INH) . paraaminosalicylic acid (PAS) compared with streptomycin (SM)⋅INH⋅PAS in the treatment of original cases of pulmonary tuberculosis.<BR>Inpatients with p ositive tubercle bacilli and/or cavities were allocated at random to one of the two regimens; 67 cases were included in the RFP⋅INH⋅PAS group and 64 cases in the SM. INH. PAS group, after exclusion of those who were discharged before completion of the th ree months treatment and one who had been proven as a primary drug resistant case.450 mg of RFP were given once daily, 1 g streptomycin twice weekly, 0.3g INH once daily and 10 g PAS daily in three divided dose after each meal. Both treatments were continued for six months. The background factors of cases in each group were almost similar. The clinical effects of the treatment were compared according to the rate of improvements of chest radiograms and bacilli conversion rate in sputa. Moderate or marked improvement of basic lesions on chest radiograms was observed in 26% after three months treatment and 53% after six months in the RFP group, while the rate was 18% after three months and 51% after six months in the SM group. The rate of moderate or marked improvement in the cavities with non-sclerotic wall after six months treatment were 34% in the RFP group and 27% in the SM group. The tubercle bacilli in sputa showed a negative conversion rate on culture in 98% after three months and 100%after six months by RFP⋅INH⋅PAS and in 84% and 95%, respectively, by SM. INH. PAS. The difference in the negative conversion rate on culture at three months in the far advanced cases was statistically significant at 5% level in favour of RFP⋅INII⋅PAS. The only side effect was allergic reactions such as fever and skin rash which were observed in one case of the RFP group and two cases of the SM group. It is concluded that RFP⋅INH⋅PAS is as good as, or may be better than SM⋅INH⋅PAS in the original treatment of pulmonary tuberculosis.

著者

• 堂野前 維摩郷

  日本結核化学療法研究会

• 藤田 真之助

  日本結核化学療法研究会

• 五味 二郎

  日本結核化学療法研究会

• 日比野 進

  日本結核化学療法研究会

• 宝来 善次

  日本結核化学療法研究会

• 伊藤 文雄

  日本結核化学療法研究会

• 岩崎 龍郎

  日本結核化学療法研究会

• 河盛 勇造

  日本結核化学療法研究会

• 北本 治

  日本結核化学療法研究会

• 長沢 潤

  日本結核化学療法研究会

• 中村 隆

  日本結核化学療法研究会

• 岡 捨己

  日本結核化学療法研究会

• 島村 喜久治

  日本結核化学療法研究会

• 杉山 浩太郎

  日本結核化学療法研究会

• 砂原 茂一

  日本結核化学療法研究会

• 徳臣 晴比古

  日本結核化学療法研究会

• 山本 和男

  日本結核化学療法研究会

• 内藤 益一

  日本結核化学療法研究会

関連論文

• Tuberactinomycin-Nによる肺結核治療の臨床的研究
• 未治療肺結核に対するSM・INH・EB併用療法
• Lividomycinの再治療重症肺結核患者に対する治療効果の研究
• Rifampicinによる肺結核治療の臨床的研究 : 第2報未治療肺結核に対するRFP・INH・PAS併用とSM・INH・PAS併用の治療効果比較
• Rifampicinによる肺結核治療の臨床的研究 : 第1報予備的研究.重症耐性肺結核に対する治療成績

スポンサーリンク